Press releases
Galenica continues to grow in 2024
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 11 March 2025
With sales up 4.7% in the 2024 financial year, the Galenica Group grew strongly and generated consolidated net sales of CHF 3,921.1 million. As a result, Galenica outperformed market growth and gained market share in all its main business areas. Adjusted1 EBIT increased by 10.3% to CHF 211.0 million. Excluding the one-off special factors in the previous year, the adjusted1 operating result (EBIT) would have increased by 4.9%. Adjusted1 net profit from continuing operations also increased by 13.4% to CHF 183.2 million. Due to this positive result, the Board of Directors will propose to the Annual General Meeting that the dividend be raised to CHF 2.30 per share, which corresponds to an increase of 4.5%.
Galenica reports strong sales growth once again
Ad hoc announcement pursuant to Art. 53 LR, Thursday, 23 January 2025
Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
Galenica increases sales growth in the third quarter
Ad hoc announcement pursuant to Art. 53 LR, Thursday, 24 October 2024
Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.8 million to the end of September 2024. With growth of 4.1%, Galenica outperformed the growth of the overall pharmaceutical market (+2.9%, IQVIA, pharmaceutical market Switzerland, YTD September 2024).